Maria Cecilia Ramello

Maria Cecilia Ramello

Auto-generated profile, based on publicly available information

Maria Cecilia Ramello

Departments of Immunology and Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
MRMaria C. Ramello
Maria C. Ramello
IBIsmahène Benzaïd
Ismahène Benzaïd
BKBrent M. Kuenzi
Brent M. Kuenzi
MLMaritza Lienlaf-Moreno
Maritza Lienlaf-Moreno
WKWendy M. Kandell
Wendy M. Kandell
DADaniel Abate-Daga
Daniel Abate-Daga
The total length of CAR intracellular domains determines interactions with endogenous proteins to promote TCR signaling.

28 June 2022 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
BMBarbara Mandriani
Barbara Mandriani
EPEleonora Pellè
Eleonora Pellè
FMFrancesco Mannavola
Francesco Mannavola
APAntonio Palazzo
Antonio Palazzo
RMRené Marsano
René Marsano
MCMauro Cives
Mauro Cives
Background Neuroendocrine tumors (NETs) overexpress somatostatin receptors (SSTRs). Methods We developed a second-generation, ligand-based, anti-SSTR chimeric antigen receptor (CAR) incorporating the somatostatin analog octreotide in its extracellular moiety. Results Anti-SSTR CAR T cells exerted antitumor activity against SSTR+NET cell linesin vitro. The killing activity was highly specific, as demonstrated by the lack of CAR T cell reactivity against NET cells engineered to express mutated variants of SSTR2/5 by CRISPR/Cas9. When adoptively transferred in NSG mice, anti-SSTR CAR T cells induced significant antitumor activity against human NET xenografts. Although anti-SSTR CAR T cells could recognize the murine SSTRs as shown by their killing ability against murine NET cells, no obvious deleterious effects on SSTR-expressing organs such as the brain or the pancreas were observed in mice. Conclusions Taken together, our results establish anti-SSTR CAR T cells as a potential candidate for early phase clinical investigations in patients with NETs. More broadly, the demonstration that a known peptide drug can direct CAR T cell targeting may streamline the potential utility of multiple peptide motifs and provide a blueprint for therapeutic applications in a variety of cancers.

24 September 2019 in BioDrugs
Verified
Journal Article
Closed access
PDF file
EREmiliano Roselli
Emiliano Roselli
JFJeremy Frieling
Jeremy Frieling
KTKonrad Thorner
Konrad Thorner
MRMaría C. Ramello
María C. Ramello
CLConor C Lynch
Conor C Lynch
DADaniel Abate-Daga
Daniel Abate-Daga

9 November 2020 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
MPMarine Potez
Marine Potez
SSSebastian Snedal
Sebastian Snedal
JKJongmyung Kim
Jongmyung Kim
KTKonrad Thorner
Konrad Thorner
MRMaria Cecilia Ramello
Maria Cecilia Ramello
JLJames Liu
James Liu
Glioblastoma (GBM) is the most aggressive primary brain tumor with high mortality rates and resistance to conventional therapy. Their resistance to conventional therapy has been attributed to the presence of cancer stem cells (CSCs), a sub-population of tumor cells capable of self-renewal and tumor initiation. Developing novel strategies to specifically target GSCs may allow more effective therapeutic strategies. Using in vivo phage display biopanning, we have identified several peptides with the potential to selectively target and bind GSCs. We wished to leverage the GSC targeting properties of the peptides to augment therapeutic delivery vehicles for the development of novel targeting strategies. We used a combination of GSC targeting peptides to modify the antigen-binding domain of chimeric antigen receptors, by arranging the peptides in tandem at the N-terminus of the CAR molecule. These tandem peptides were tested for binding to GSCs in vitro and in vivo. The functionality of the CAR-T cells was evaluated by measuring cytokine release in the supernatant after overnight co-culture through ELISA. Apoptosis was evaluated by flow cytometry with Annexin V staining. Two different GSC-targeting peptide CAR-T cells demonstrated specific targeting GSCs. Following co-culture with GSCs, GSC targeting CAR-T cells were activated with release of Interferon gamma and subsequently induced GSCs specific apoptosis. These results demonstrate the use of phage display biopanning to isolate GSC targeting peptides which may be used to develop novel GBM specific cytotoxic therapies.